Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study

Ronald B. Natale, David Bodkin, Ramaswamy Govindan, Bethany G. Sleckman, Naiyer A. Rizvi, Adolfo Capó, Paul Germonpré, Wilfried E.E. Eberhardt, Paul K. Stockman, Sarah J. Kennedy, Malcolm Ranson

Research output: Contribution to journalArticlepeer-review

181 Scopus citations

Fingerprint

Dive into the research topics of 'Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences